Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
NUVB Stock Forecast 2026-2027
$5.80
Current Price
$1.96B
Market Cap
Buy 9
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to NUVB Price Targets
+227.6%
To High Target of $19.00
+106.9%
To Median Target of $12.00
+20.7%
To Low Target of $7.00
NUVB Price Momentum
-0.2%
1 Week Change
+4.3%
1 Month Change
+152.2%
1 Year Change
-35.3%
Year-to-Date Change
-40.5%
From 52W High of $9.75
+166.1%
From 52W Low of $2.18
📊 TOP ANALYST CALLS
Did NUVB Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Nuvation Bio is one of their latest high-conviction picks.
Latest NUVB Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, NUVB has a bullish consensus with a median price target of $12.00 (ranging from $7.00 to $19.00). The overall analyst rating is Strong Buy (9.2/10). Currently trading at $5.80, the median forecast implies a 106.9% upside. This outlook is supported by 9 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Leonid Timashev at RBC Capital, projecting a 227.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
NUVB Analyst Ratings
9
Buy
1
Hold
0
Sell
NUVB Price Target Range
Low
$7.00
Average
$12.00
High
$19.00
Current: $5.80
Latest NUVB Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for NUVB.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jul 7, 2026 | RBC Capital | Leonid Timashev | Outperform | Maintains | $19.00 |
| Jul 7, 2026 | Truist Securities | Gregory Renza | Buy | Maintains | $13.00 |
| May 5, 2026 | RBC Capital | Outperform | Reiterates | $N/A | |
| May 5, 2026 | Wedbush | Outperform | Reiterates | $N/A | |
| May 5, 2026 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Apr 16, 2026 | Wedbush | Outperform | Reiterates | $N/A | |
| Apr 2, 2026 | Wedbush | Outperform | Reiterates | $N/A | |
| Mar 27, 2026 | Wedbush | Outperform | Reiterates | $N/A | |
| Mar 3, 2026 | UBS | Neutral | Maintains | $N/A | |
| Mar 3, 2026 | RBC Capital | Outperform | Maintains | $N/A | |
| Feb 10, 2026 | Wedbush | Outperform | Reiterates | $N/A | |
| Jan 21, 2026 | RBC Capital | Outperform | Maintains | $N/A | |
| Jan 12, 2026 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Jan 7, 2026 | UBS | Neutral | Initiates | $N/A | |
| Dec 11, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Dec 1, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Nov 24, 2025 | Truist Securities | Buy | Initiates | $N/A | |
| Nov 20, 2025 | Citizens | Market Outperform | Maintains | $N/A | |
| Nov 19, 2025 | B. Riley Securities | Buy | Initiates | $N/A | |
| Nov 4, 2025 | RBC Capital | Outperform | Maintains | $N/A |
Nuvation Bio Inc. (NUVB) Competitors
The following stocks are similar to Nuvation Bio based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
NUVB
Nuvation Bio
mkt cap
2.02B
Nuvation Bio Inc. (NUVB) Financial Data
Nuvation Bio Inc. has a market capitalization of $1.96B with a P/E ratio of -9.4x. The company generates $143.05M in trailing twelve-month revenue with a -102.1% profit margin.
Revenue growth is +2,598.7% quarter-over-quarter, while maintaining an operating margin of +4.7% and return on equity of -39.5%.
Valuation Metrics
Market Cap
$1.96B
Enterprise Value
$1.74B
P/E Ratio
-9.4x
PEG Ratio
0.1x
Price/Sales
14.4x
Growth & Margins
Revenue Growth (YoY)
+2,598.7%
Gross Margin
+92.8%
Operating Margin
+4.7%
Net Margin
-102.1%
EPS Growth
+2,598.7%
Financial Health
Cash/Price Ratio
+26.4%
Current Ratio
7.4x
Debt/Equity
67.9x
ROE
-39.5%
ROA
-17.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Nuvation Bio Inc. (NUVB) Business Model
About Nuvation Bio Inc.
What They Do
Develops targeted oncology therapies for cancer treatment.
Business Model
Nuvation Bio operates as a commercial-stage biopharmaceutical company focused on developing and commercializing oncology therapies. The company generates revenue by selecting, developing, and regulating specialized medicines, primarily through targeted small-molecule drugs and innovative drug-drug conjugates.
Additional Information
Founded in 2018 and headquartered in New York, Nuvation Bio also has offices in San Francisco, Boston, and Shanghai. The company is positioned within the high-demand market for precision oncology, targeting cancers with significant unmet medical needs.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
307
CEO
Dr. David T. Hung M.D.
Country
United States
IPO Year
1999
Website
www.nuvationbio.comNuvation Bio Inc. (NUVB) Latest News & Analysis
Latest News
Quick Summary
Nuvation Bio Inc. (NYSE: NUVB) announced the full exercise of its over-allotment option, raising an additional $37.5 million from its 0.75% Convertible Senior Notes, totaling $287.5 million.
Why It Matters
Nuvation Bio's successful Greenshoe Exercise indicates strong demand for its convertible notes, enhancing liquidity and financial stability while signaling investor confidence in its oncology developments.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Nuvation Bio executive Markel Stacy sold 125,000 Class A shares for $753,000, reducing her direct holdings to 32,591 shares, while maintaining exposure via stock options.
Why It Matters
The executive's significant share sale may signal a lack of confidence in the company's future, potentially impacting investor sentiment and stock performance.
Source: The Motley Fool
Market Sentiment:
Neutral
Quick Summary
The press release is intended exclusively for U.S. audiences and is not intended for distribution to a U.K. audience.
Why It Matters
The restriction to U.S. audiences may indicate regulatory or market-specific implications, potentially affecting stock performance and investor sentiment in relevant sectors.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Nuvation Bio Inc. plans to offer $200 million in Convertible Senior Notes due in 2032, with an option for underwriters to purchase an additional $30 million for over-allotments.
Why It Matters
Nuvation Bio's $200 million convertible notes offering signals potential for growth funding, impacting stock valuation and investor sentiment in the oncology sector.
Source: PRNewsWire
Market Sentiment:
Neutral
Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes
22 days ago
Quick Summary
Nuvation Bio Inc. has priced an underwritten offering of $250 million in 0.75% Convertible Senior Notes due 2032, up from an initially announced $200 million.
Why It Matters
Nuvation Bio's increased offering of $250 million in convertible notes indicates strong investor demand and may enhance its capital for oncology developments, influencing stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Nuvation Bio initiated with a Moderate Buy rating, citing undervaluation of oncology assets. Fair value estimated at $5.6/share, with potential upside from M&A and milestone payments.
Why It Matters
Nuvation Bio's valuation suggests upside potential, driven by its oncology assets and M&A prospects, which could enhance shareholder value and attract investor interest.
Source: Seeking Alpha
Market Sentiment:
Positive
Frequently Asked Questions About NUVB Stock
What is Nuvation Bio Inc.'s (NUVB) stock forecast for 2027?
Based on our analysis of 3 Wall Street analysts, Nuvation Bio Inc. (NUVB) has a median price target of $12.00. The highest price target is $19.00 and the lowest is $7.00.
Is NUVB stock a good investment in 2027?
According to current analyst ratings, NUVB has 9 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $5.80. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for NUVB stock?
Wall Street analysts predict NUVB stock could reach $12.00 in the next 12 months. This represents a 106.9% increase from the current price of $5.80. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Nuvation Bio Inc.'s business model?
Nuvation Bio operates as a commercial-stage biopharmaceutical company focused on developing and commercializing oncology therapies. The company generates revenue by selecting, developing, and regulating specialized medicines, primarily through targeted small-molecule drugs and innovative drug-drug conjugates.
What is the highest forecasted price for NUVB Nuvation Bio Inc.?
The highest price target for NUVB is $19.00 from Leonid Timashev at RBC Capital, which represents a 227.6% increase from the current price of $5.80.
What is the lowest forecasted price for NUVB Nuvation Bio Inc.?
The lowest price target for NUVB is $7.00 from at , which represents a 20.7% increase from the current price of $5.80.
What is the overall NUVB consensus from analysts for Nuvation Bio Inc.?
The overall analyst consensus for NUVB is bullish. Out of 3 Wall Street analysts, 9 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $12.00.
How accurate are NUVB stock price projections?
Stock price projections, including those for Nuvation Bio Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 18, 2026 2:45 AM UTC